i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

Trial Starti-Lumen AMD SystemPositive

AI Analysis

Summary

i-Lumen Scientific announced the first U.S. patient enrollment in the i-SIGHT2 pivotal study evaluating the i-Lumen AMD System, a noninvasive bioelectric therapy for intermediate to advanced dry age-related macular degeneration.

Clinical Trial Data

Phase

pivotal

Outcome Details

First U.S. patient randomized in i-SIGHT2 pivotal study

Importance:5/10

Sentiment:

0.60

clinical trialmedical deviceophthalmologydry AMDbioelectric therapy

Related Companies

$MDCE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 21, 2026 1:00 PM

Read Original